Oncocross Co Ltd
382150
Company Profile
Business description
Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI.
Contact
Saechang-ro
11, 15, 16th floor
Mapo-gu
Seoul
KORT: +82 28679967
Sector
Technology
Stock type
Sensitive
Industry
Software - Infrastructure
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.30 | 45.10 | -0.50% |
| CAC 40 | 7,808.92 | 9.36 | -0.12% |
| DAX 40 | 24,107.74 | 188.19 | -0.77% |
| Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
| FTSE 100 | 9,097.50 | 40.87 | -0.45% |
| HKSE | 25,388.35 | 278.83 | -1.09% |
| NASDAQ | 21,057.96 | 37.94 | 0.18% |
| Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
| NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
| S&P 500 | 6,363.35 | 4.44 | 0.07% |
| S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
| SSE Composite Index | 3,593.66 | 12.07 | -0.33% |